Flubromazolam

Flubromazolam is a benzodiazepine derivative which was first synthesized in 1976, but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a research chemical. It produces strong tranquilizing effects, including sedation, muscle relaxation and anxiety suppression.

Chemistry

Flubromazolam is a member of the benzodiazepine class as it contains a 1,4 diazepine ring fused to a substituted benzene ring. It is structurally related to flubromazepam due to the presence of a fluorine atom in its structure.

Pharmacology

Flubromazolam acts as a full agonist of the benzodiazepine receptor to produce its range of therapeutic and adverse effects. According to its molecular structure, it is classified as a triazolo-benzodiazepine, which are known to be more potent than regular benzodiazepines.

Effects

Flubromazolam has been noted for its potential use in the short-term treatment of anxiety, insomnia, acute seizures, and the sedation of hospitalized patients. However, it is currently sold as a research chemical and not approved for human consumption.

Legal Status

As of October 2015, flubromazolam is a controlled substance in China. In the United Kingdom, it has been a Class C drug since May 2017. It is also a controlled substance in some other countries.

See Also

• Benzodiazepine
• Flubromazepam
• Research chemical

References

<references />

• 
  Flubromazolam